共查询到20条相似文献,搜索用时 781 毫秒
1.
目的探讨转移性骨肿瘤患者的临床特点,提高临床诊治水平。方法回顾性分析转移性骨肿瘤患者的原发肿瘤来源、骨转移部位、发生时间及病理类型。结果原发肿瘤来源前5位依次为:肺癌(49.3%),乳腺癌(7.9%),前列腺癌(6.1%),食管癌(5.8%),原发病灶不明骨转移肿瘤(5.0%)和结直肠癌(5.0%);前5位的常见骨转移部位依次为肋骨(161例),胸椎(138例)、腰椎(132例)、骨盆(106例)和股骨(65例)。159例患者在原发肿瘤确诊时已经发现骨转移,其余119例患者平均转移时间为10.7个月;全组中位生存期为17.2个月。137例肺癌骨转移病例中,腺癌最常见(40.9%)。结论对肺癌(尤其是肺腺癌)、食管癌及肝癌患者应提高警惕,尽早行相关检查,及时发现骨转移,以采取有效的干预措施。 相似文献
2.
3.
转移性骨肿瘤分子机制的研究进展 总被引:2,自引:2,他引:0
转移性骨肿瘤的发生率约占全身转移性肿瘤的15%~20%,仅次于肺转移和肝转移,居第三位。原发灶以前列腺癌、乳腺癌最常见,容易出现骨转移的肿瘤还有肺癌、肾癌、甲状腺癌和黑色素瘤。在分子水平上阐述转移性骨肿瘤的发生机制,对关键环节进行干预,将成为今后防治转移性骨肿瘤,提高患者生存质量的重要课题。现将转移性骨肿瘤分子机制的研究进展综述如下。 相似文献
4.
390例病理确诊转移性骨肿瘤的临床分析 总被引:6,自引:0,他引:6
背景与目的:随着影像、病理等诊断技术的提高,转移性骨肿瘤的早期诊断得到明显改善,但其临床特点复杂,少见报道。本文旨在总结分析经过病理确诊的转移性骨肿瘤病例的临床特点,以进一步提高临床早期诊断和治疗水平。方法:回顾性分析1980年1月至2003年12月我院病理确诊的转移性骨肿瘤390例,总结转移性骨肿瘤的病史、好发部位、临床表现、影像学等临床特点。结果:390例转移性骨肿瘤中,男女比为2.12∶1,中位年龄55.7岁,41岁以上者占81.5%。原发肿瘤依次为肺癌85例(21.8%)、前列腺癌51例(13.1%)、乳腺癌29例(7.4%)、肝癌25例(6.4%)、胃肠癌22例(5.7%);来源不明占96例(24.6%)。脊柱受累占47.7%,其次为骨盆18.2%、股骨15.4%、肋骨12.6%,全身多处转移占20.5%。患者常因骨痛(53.3%)、肿物(14.1%)、病理性骨折(10.3%)、功能障碍(4.9%)甚至截瘫(2.1%)等就诊。原发瘤先被发现的占29.7%,中位转移时间为319天,70.3%的患者不能确定骨转移时间。影像学以溶骨性改变(80.7%)多见,其次为成骨性改变(10.5%)、混合型。结论:转移性骨肿瘤的临床特征复杂,但仍有一定的规律性:(1)转移性骨肿瘤好发于41岁以上的患者;(2)肺癌、前列腺癌、乳腺癌、肝癌最常发生骨转移,以脊柱受累最为常见,其次为骨盆、股骨、肋骨;(3)临床表现多样而无特异性;(4)影像学表现以溶骨性破坏为主;(5)原发灶不明占24%,应掌握其发病特点争取早期诊断、早期治疗。 相似文献
5.
6.
7.
8.
9.
10.
11.
目的:探讨乳腺癌骨转移患者的临床、病理、治疗及预后因素。方法:收集2005年1 月至2013年4 月天津医科大学肿瘤医院收治的183 例至少接受6 个月双膦酸盐治疗的乳腺癌骨转移患者的临床资料,根据双膦酸盐类型分为帕米膦酸二钠组、唑来膦酸组及帕米膦酸二钠序贯唑来膦酸组,探讨骨转移的特点、骨相关事件(skeletal-related events,SREs)、治疗及预后特征。结果:胸椎和肋骨为骨转移的常见转移部位,骨转移至发生首次SREs的中位时间为4.2 个月,51.9%(95/ 183)患者发生SREs,累计SREs事件数达167 次,其中110 次(65.9%)发生在骨转移后1 年内,SREs类型以骨放疗为主。患者在不同双膦酸盐药物组的SREs发生率差异无统计学意义(P > 0.05)。 183 例患者骨转移后的中位生存期为43.1 个月,激素受体状态、无病生存期、是否合并内脏转移及脊柱转移与否是乳腺癌骨转移患者的独立预后因素(P < 0.05)。 结论:胸椎和肋骨是乳腺癌骨转移的常见转移部位,SREs主要发生在骨转移后1 年内并以骨放疗为主。激素受体阴性、无病生存期短、合并内脏及脊柱转移是影响乳腺癌患者骨转移不良预后的独立因素。 相似文献
12.
13.
Risk Factors,Patterns, and Distribution of Bone Metastases and Skeletal-Related Events in High-Risk Breast Cancer Patients 下载免费PDF全文
Sumadi Lukman AnwarWidya Surya AvantiEry Kus DwianingsihRoby CahyonoSuwardjo Suwardjo 《Asian Pacific journal of cancer prevention》2022,23(12):4109-4117
Background: More than a quarter of breast cancer patients are at risk to develop recurrent metastases to the bone. Objective: This study was designed to identify risk factors and predilections of bone metastasis and skeletal-related events (SRE) in a population of breast cancer survivors initially diagnosed in advanced stages and with high-risks of relapse. Methods: Associated risk factors, distribution, and attainable treatment of bone metastasis and SRE were analyzed in a cohort of 1,329 breast cancer patients. The association with dependent variables was subsequently analyzed using multivariable logistic regression. Sociodemographic and adverse clinical characteristics were included as covariates of progression into bone metastasis and SREs. Results: Of 1329 breast cancer patients, 246 patients (18.5%) were diagnosed as metastatic breast cancer in which 232 of them (94.3%) had bone metastases. Spines were the most common sites of bone metastases (25.6%). In multivariable analysis, advanced stage at diagnosis (OR=1.840, 95%CI:1.198-2.826, P=0.005), luminal subtype (OR=1.788, 95%CI:1.206-2.652, P=0.045), lobular histology (OR=1.795, 95%CI:1.012-3/184, P=0.046), positive axillary lymph node (OR=1.771, 95%CI:1.087-2.886, P=0.022), multiple metabolic comorbidities (OR=2.193, 95%CI:1.371-3.508, P=0.001), early menopause (OR=2.136, 95%CI:1.116-4.464, P=0.046) were significantly associated with risk of recurrent bone metastases. SREs occurred in 89 (68.5%) patients. Several risk factors for SREs were early menopausal age (OR=2.342, P=0.024), advanced stages (OR=1.404, P=0.039), lobular histology (OR=2.279, P=0.007), and having multiple metabolic comorbidities (OR=1.728, P=0.039). Conclusion: Bone metastases and SREs are relatively high in breast cancer patients diagnosed in advanced stages. Luminal subtypes, having multiple metabolic comorbidities, and lobular histology are associated with higher risks of recurrent bone metastases. Living in rural areas and advanced stage at diagnosis as a risk factors for bone metastases might represent a social gradient of care delivery. 相似文献
14.
Extracranial metastases and their frequency by sites have been described as prognostic factors for survival of patients with
brain metastasis. However, these factors must be identified and described in more detail for a large series of patients. Using
routine data from the largest German health insurance fund, 5,074 patients with brain metastasis who were diagnosed and treated
in 2008 were analyzed to identify the frequency and distribution of extracranial metastatic sites concurrent with brain metastasis
in relation to age, gender, and tumor type. Brain metastases were observed in males more frequently than in females (56.4
and 43.6% respectively P < 0.001), and were most often from lung (51.2%), breast (12.3%), and unknown (7.5%) primaries. Extracranial metastatic sites
were observed in 58.8% of patients; the number of sites was from 1 to 7, with a mean of 1.11. For the 16 most common primary
sites the range was from 0.13 to 1.91 . In 11 of these 16 sites, lungs were the most common concurrent metastatic site. Lung
cancer, breast cancer, non-Hodgkin’s lymphoma, and testicular cancer most commonly metastasized to bone, and bladder cancer
to kidneys. Different primary tumors have different frequencies and patterns of extracranial metastatic sites concurrently
with brain metastasis. The lung is the most common metastatic site of most primary tumors, bone for a few tumors, and kidneys
for bladder cancer. For the unknown primary tumor type, screening for these most common metastatic sites must be intensified,
in particular when molecular assessment is not available. 相似文献
15.
16.
Ruiterkamp J Ernst MF de Munck L van der Heiden-van der Loo M Bastiaannet E van de Poll-Franse LV Bosscha K Tjan-Heijnen VC Voogd AC 《Breast cancer research and treatment》2011,129(2):495-503
Bone lesions as a consequence of bone metastases in breast cancer patients can increase risk for skeletal-related events (SREs)
(i.e., radiation to the bone, a pathological or osteoporotic fracture event, hypercalcemia, spinal cord compression, or surgery
to the bone). The mortality risk for breast cancer patients with SREs subsequent to bone metastases is unclear. We assessed
this relationship in a large, population-based cohort of breast cancer patients in Denmark. We identified 35,912 newly diagnosed
breast cancer patients from January 1, 1999 to December 31, 2007 in the Danish National Patient Registry (DNPR) and followed
them through April 1, 2008. Information on stage and treatment was obtained from the Danish Cancer Registry. We used the Kaplan–Meier
method to estimate survival, and Cox’s regression analysis to estimate the mortality rate ratio (MRR) by the presence of bone
metastases with and without SREs, adjusting for age and comorbidity. The 5-year survival was 75.8% for breast cancer patients without bone metastases, 8.3% for patients with bone metastases,
and 2.5% for those with both bone metastases and SREs. The adjusted MRR was 10.5 [95% confidence interval (CI) 9.5–11.6] for
breast cancer patients with bone metastases, and 14.4 (95% CI 13.1–15.8) for those with bone metastases and SREs, compared
with breast cancer patients with no bone metastases but possibly other sites of metastases. A similar pattern persisted when
analyses were stratified by stage or treatment. Breast cancer patients with bone metastases and SREs have a poor prognosis
compared to those with and without bone metastases regardless of cancer treatment or stage of disease at diagnosis. 相似文献
17.
骨骼是乳腺癌最常见的远处转移部位,约占所有转移性乳腺癌患者的60%~75%。骨转移灶形成的软组织包块可对周围重要神经血管形成压迫,导致肢体局部功能丧失,骨痛、病理性骨折、脊髓压迫及高钙血症等骨相关事件的出现,严重影响患者的自主活动能力及生存质量。为早期识别乳腺癌骨转移、控制骨转移灶进展并对骨转移灶及时进行干预,从而改善患者的生存质量,中国抗癌协会骨肿瘤和骨转移瘤专业委员会组织编写《乳腺癌骨转移诊疗专家共识》,以期对乳腺癌骨转移患者的诊疗给予指导与帮助。 相似文献
18.
19.
20.
Santini D Tampellini M Vincenzi B Ibrahim T Ortega C Virzi V Silvestris N Berardi R Masini C Calipari N Ottaviani D Catalano V Badalamenti G Giannicola R Fabbri F Venditti O Fratto ME Mazzara C Latiano TP Bertolini F Petrelli F Ottone A Caroti C Salvatore L Falcone A Giordani P Addeo R Aglietta M Cascinu S Barni S Maiello E Tonini G 《Annals of oncology》2012,23(8):2072-2077
BackgroundData are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC.Patients and methodsThis retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes.ResultsMost patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.ConclusionThis study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting. 相似文献